Viyash Scientific Limited (NSE:VIYASH)
246.30
-1.24 (-0.50%)
May 22, 2026, 3:30 PM IST
Viyash Scientific Revenue
In the fiscal year ending March 31, 2026, Viyash Scientific had annual revenue of 34.20B INR with 120.47% growth. Viyash Scientific had revenue of 9.20B in the quarter ending March 31, 2026, with 129.02% growth.
Revenue
34.20B
Revenue Growth
+120.47%
P/S Ratio
3.14
Revenue / Employee
27.49M
Employees
1,244
Market Cap
107.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 34.20B | 18.69B | 120.47% |
| Mar 31, 2025 | 15.51B | 1.82B | 13.26% |
| Mar 31, 2024 | 13.70B | -511.78M | -3.60% |
| Mar 31, 2023 | 14.21B | 80.93M | 0.57% |
| Mar 31, 2022 | 14.13B | 512.01M | 3.76% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 88.69B |
| Alembic Pharmaceuticals | 73.45B |
| Strides Pharma Science | 48.59B |
| NATCO Pharma | 45.63B |
| Akums Drugs and Pharmaceuticals | 43.59B |
| Eris Lifesciences | 31.37B |
| Alivus Life Sciences | 25.52B |
| Cohance Lifesciences | 23.03B |
Viyash Scientific News
- 6 months ago - Sequent Scientific Ltd (BOM:512529) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 6 months ago - Q2 2026 SeQuent Scientific Ltd Earnings Call Transcript - GuruFocus
- 6 months ago - SeQuent Scientific shares jump over 10% as NCLT approves merger with Viyash Lifesciences - Business Upturn
- 1 year ago - Sequent Scientific Q4 Results: Revenue up 11% YoY to Rs 401 crore - Business Upturn
- 1 year ago - Sequent Scientific Ltd (BOM:512529) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - GuruFocus
- 1 year ago - Sequent Scientific Q3 FY25 results: Revenue up 18.7% YoY to Rs 390.8 crore, Net profit declines 58.5% YoY - Business Upturn
- 1 year ago - India's Animal Healthcare Industry on a High-Growth Trajectory, Projected to Reach USD 2.0 Billion by 2034| Exclusive Report by Transparency Market Research Inc. - Benzinga
- 1 year ago - SeQuent Scientific consolidates ownership of subsidiaries in Sweden and Italy - Business Upturn